2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication
Open accessThe DOI matches its Crossref record; 68 of the 70 references it cites were found in a registry or an index.
Abstract
The persistence of the AIDS epidemic, and the life-long treatment required, indicate the constant need of novel HIV-1 inhibitors. In this scenario the HIV-1 Reverse Transcriptase (RT)-associated ribonuclease H (RNase H) function is a promising drug target. Here we report a series of compounds, developed on the 2-amino-6-(trifluoromethyl)nicotinic acid scaffold, studied as promising RNase H dual inhibitors. Among the 44 tested compounds, 34 inhibited HIV-1 RT-associated RNase H function in the low micromolar range, and seven of them showed also to inhibit viral replication in cell-based assays with a selectivity index up to 10. The most promising compound, 21, inhibited RNase H function with an IC50 of 14 µM and HIV-1 replication in cell-based assays with a selectivity index greater than 10. Mode of action studies revealed that compound 21 is an allosteric dual-site compound inhibiting both HIV-1 RT functions, blocking the polymerase function also in presence of mutations carried by circulating variants resistant to non-nucleoside inhibitors, and the RNase H function interacting with conserved regions within the RNase H domain. Proving compound 21 as a promising lead for the design of new allosteric RNase H inhibitors active against viral replication with not significant cytotoxic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, NNRTIs were found to modulate RNH activity upon recognition of the NNRTI binding site in the polymerase domain [101-103].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063 · cited 1×
“While the highly-active antiretroviral therapy (HAART) allows patients who receive optimum treatment a life-expectation comparable to that of the uninfected population [2,3], the sub-optimal adherence and coverage of seropositive people, coupled with life-long treatment, still cause emergence of drug-resistant variant…”
BackgroundUPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569 · cited 1×
“Luciferase activity was measured as reported [67].”
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570 · cited 1×
“HIV-1 RT-associated RNase H is an enzymatic function present in all the members of the Ortervirales order [10] and it belongs to the nucleotidyltransferase family, characterized by a highly conserved Asp-Asp-Glu (DDE) motif, essential for coordination of two Mg2+ ions, and by a tertiary structure [11] conserved among…”
BackgroundPolypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479 · cited 1×
“Dual inhibitors are a new class of molecules that aim to increase the efficacy of the drug and raise the genetic barrier to overcome the selection of resistant strains by hitting two targets at the same time [44,51,52].”
BackgroundPolypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465 · cited 1×
“Dual inhibitors are a new class of molecules that aim to increase the efficacy of the drug and raise the genetic barrier to overcome the selection of resistant strains by hitting two targets at the same time [44,51,52].”
BackgroundGregson, J., Tang, M., Ndembi, N., Hamers, R. L., Rhee, S.-Y., Marconi, V. C., Diero, L., Brooks, K. A., Theys, K., Rinke de Wit, T., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00536-8 · Cited by 267
2019 update of the drug resistance mutations in HIV-1.
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Paredes, R., Shafer, R. W., & Richman, D. D. (2019) · PubMed · Cited by 230
Tadokoro, T., & Kanaya, S. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.06907.x · Cited by 202
Collective Motions in HIV-1 Reverse Transcriptase: Examination of Flexibility and Enzyme Function
Bahar, I., Erman, B., Jernigan, R. L., Atilgan, A. R., & Covell, D. G. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2371 · Cited by 201 · cited 1×
“In the constant need to identify and develop new anti-HIV drugs, possibly active against circulating drug-resistant variants, this approach has been applied to RDDP/Integrase and RNase H/Integrase dual inhibitors [53–61], that target two different viral enzymes, and to RNase H/RDDP dual inhibitors, that target two dis…”
Method
Cited by
Du, S., Hu, X., Menéndez‐Arias, L., Zhan, P., & Liu, X. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101053 · Cited by 61
Zhang, K., Zhang, Y., Li, M., Pannecouque, C. C., Clercq, E. D., Wang, S., & Chen, F. (2024) · Medicinal Research Reviews · doi:10.1002/med.22080 · Cited by 35
Recent Trends in Enzyme Inhibition and Activation in Drug Design
Geronikaki, A. A. (2020) · Molecules · doi:10.3390/molecules26010017 · Cited by 25
“[3] presented the synthesis and testing of forty-four compounds based on 2-amino-6-(trifluoromethyl)nicotinic acid scaffold as promising RNase H dual inhibitors.”
MethodCurrent medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors
Zhang, L., Wei, F., Zhang, J., Liu, C., López‐Carrobles, N., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114760 · Cited by 20
Kang, J.-X., Zhao, G.-K., Yang, X., Huang, M.-X., Hui, W., Zeng, R., & Ouyang, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115196 · Cited by 19
Metadata
- Authors
- Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E.
- Affiliations
- University of Cagliari (IT)
- Department of Molecular Medicine, University of Padova, 35121 Padova, Italy
- Yale University (US)
- University of Padua (IT)
- Corresponding author
- Tramontano, Enzo
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-03-15
- Volume
- 25
- Issue
- 6
- Pages
- 1338
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7144554
- OpenAlex
- W3012081745
- Semantic Scholar
- 1d399d23a40a38222ce6a1e4c0b8836319f84d91
- Cited by
- 19
- References
- 70
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 2
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, cc-by)
- Funders
- Regione Autonoma della Sardegna (F76C18000800002)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- HIV-1 reverse transcriptase, RNase H, dual inhibitors, allosteric inhibitors, HIV-1 replication inhibition, antiviral drug design, non-nucleoside reverse transcriptase inhibitors, drug selectivity index, viral replication
- MeSH terms
- Allosteric Regulation, Humans, Virus Replication, HIV-1, Ribonuclease H, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Cell Line, Tumor, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication. https://app.cochat.ai/papers/10.3390/molecules25061338
- The paper
- Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E. (2020). 2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication. Molecules. https://doi.org/10.3390/molecules25061338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.